Impact of Genotyping Errors on Type I Error Rate of the Haplotype-Sharing Transmission/Disequilibrium Test (HS-TDT)  by Knapp, Michael & Becker, Tim
Letters to the Editor 589
or 100 genetic tests might be available formany common
diseases. If there are numerous predisposing alleles and
each has an independent odds ratio of only 1.5–1.7, the
overall effect would still be substantial. We simulated
models of 10, 15, and 20 genes with a risk of 1.5–1.7
each and found the areas under the ROC curves (AUCs)
to be 0.70, 0.74, and 0.77, respectively. The discrimi-
natory ability of 20 gene tests, each with an odds ratio
of 1.5–1.7, is comparable with the test of total choles-
terol level for prediction of coronary heart disease (Wil-
son et al. 1998). The effect would be even greater if only
5% or 10% of all alleles tested had odds ratios in the
range of 2.5–3.5 or if we could identify combinations
of a few genes and/or gene-environment interactions that
are strong predictors of the disease.
The comments of Janssens et al. also raise several in-
teresting points regarding different perspectives on mul-
tiple genetic testing. Epidemiologic studies, including
those on the utility of ROC curves for screening, provide
a useful population perspective. In contrast, clinicians
usually focus on individual patients rather than on the
population as a whole, and this focus will be enhanced
by the development of personalized genomic medicine
(Roses 2000; Jain 2002). It is true that no more than a
few people per million might turn out to have a very
high risk deﬁned by positive results for multiple genetic
tests for a particular disease. However, it might be very
important to these few people to know that they are at
high risk if an intervention is available to prevent the
disease. Our likelihood-ratio–based method provides an
approach that is useful for individual patients and their
physicians in predicting the probability of developing
disease.
QUANHE YANG,1 MUIN J. KHOURY,2
LORENZO BOTTO,1 J. M. FRIEDMAN,4 AND
W. DANA FLANDERS3
1National Center on Birth Defects and Developmental
Disabilities and 2Ofﬁce of Genomics and Disease
Prevention, Centers for Disease Control and
Prevention (CDC), and 3Department of Epidemiology,
School of Public Health, Emory University, Atlanta;
and 4Department of Medical Genetics, University of
British Columbia, Vancouver
References
Fletcher SW (1997) Whither scientiﬁc deliberation in health
policy recommendations? Alice in the Wonderland of breast-
cancer screening. N Engl J Med 336:1180–1183
Hanley JA (1989) Receiver operating characteristic (ROC)
methodology: the state of the art. Crit Rev Diagn Imaging
29:307–335
Harris R, Lohr KN (2002) Screening for prostate cancer: an
update of the evidence for the U.S. Preventive Services Task
Force. Ann Intern Med 137:917–929
Jain KK (2002) Personalized medicine. Curr Opin Mol Ther
4:548–558
Janssens ACJW, Pardo MC, Steyerberg EW, van Duijn CM
(2004) Revisiting the clinical validity of multiplex genetic
testing in complex diseases. Am J Hum Genet 74:585–588
(in this issue)
Roses AD (2000) Pharmacogenetics and the practice of med-
icine. Nature 405:857–865
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz
H, Kannel WB (1998) Prediction of coronary heart disease
using risk factor categories. Circulation 97:1837–4187
Yang Q, Khoury MJ, Botto L, Friedman JM, Flanders WD
(2003) Improving the prediction of complex diseases by test-
ing for multiple disease-susceptibility genes. Am J Hum Ge-
net 72:636–649
Address for correspondence and reprints: Dr. Quanhe Yang, National Center
on Birth Defects and Developmental Disabilities (CDC), 1600 Clifton Road,MS
E-86, Atlanta, GA 30333. E-mail: qay0@cdc.gov
 2004 by The American Society of Human Genetics. All rights reserved.
0002-9297/2004/7403-0030$15.00
Am. J. Hum. Genet. 74:589–591, 2004
Impact of Genotyping Errors on Type I Error Rate of
the Haplotype-Sharing Transmission/Disequilibrium
Test (HS-TDT)
To the Editor:
In a recent issue of the Journal, Zhang et al. (2003)
proposed a haplotype-sharing transmission/disequilib-
rium test (HS-TDT) for the null hypothesis of no linkage
or no association between a disease and a chromosomal
region in which several tightly linked markers have been
typed. Their method is applicable to data of nuclear
families without phase information. The general idea of
their approach is to compare the similarity of the trans-
mitted haplotypes with the similarity of the nontrans-
mitted haplotypes. If the chromosomal region contains
a susceptibility locus, it is expected that the haplotypes
being transmitted to affected children are more similar
than parental haplotypes that have not been transmitted.
This reasoning seems intuitively appealing. However, it
may be supposed that a larger observed similarity for
transmitted than for nontransmitted haplotypes is not
necessarily due to the presence of a disease-susceptibility
locus but can be a consequence of undetected genotyping
errors. The proportion of genotyping errors that result
in a Mendelian inconsistency (MI) is relatively small for
family trios (Gordon et al. 1999). More important, in
the context of HS-TDT, is the fact that the chance to
detect a genotyping error differs for transmitted and
nontransmitted haplotypes. Obviously, mistyping of an
allele on a nontransmitted parental haplotype can never
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Table 1
Estimates (Based on 1,000 Replicated Samples) of
the True Type I Error Rate of HS-TDT in the
Absence of Genotyping Errors for Nominal Type I
Error a and for Two Different AOs to Handle
Ambiguous Families
N
ESTIMATED TRUE TYPE I ERROR RATE
AO1 AO2
a p .05 a p .01 a p .05 a p .01
100 .049 .009 .045 .006
200 .061 .009 .061 .009
1,000 .045 .010 .045 .010
Table 2
Estimates (Based on 1,000 Replicated Samples) of the True Type I Error Rate of
HS-TDT (AO1) in the Presence of Genotyping Errors for Nominal Type I Error a
and for Three Different Options to Handle MIs
N 
ESTIMATED TRUE TYPE I ERROR RATE
EO1 EO2 EO3
a p .05 a p .01 a p .05 a p .01 a p .05 a p .01
100 .01 .576 .297 .471 .228 .540 .264
100 .005 .215 .079 .219 .075 .208 .075
200 .005 .389 .164 .393 .146 .383 .164
1,000 .001 .146 .039 .167 .045 .147 .039
result in a MI and, therefore, cannot become prominent.
Another way to understand this problem is to imagine
that transmitted haplotypes are partially checked for
their integrity, whereas there is no such checking at all
for the nontransmitted haplotypes. A single error oc-
curring at one locus of a haplotype, however, can have
a tremendous effect on the measure of similarity of this
haplotype with all other haplotypes. Thus, nontrans-
mitted haplotypes can appear less similar than trans-
mitted haplotypes as a result of undetected genotyping
errors. In statistical terms, genotyping errors may lead
to an inﬂated type I error rate for the HS-TDT.
To quantify the magnitude of this inﬂation, we per-
formed a simulation study. Our simulation study as-
sumes that, for 19 tightly linked and equidistant diallelic
marker loci, only 29 different haplotypes occur in the
population. This set of haplotypes and the correspond-
ing frequencies are shown in table A of the online-only
supplemental material. For all family trios, we generate
the parents’ genotypes according to this haplotype dis-
tribution. The haplotype pair in the child is obtained by
randomly selecting one of the two haplotypes in each
parent. Next, genotyping errors are introduced indepen-
dently into the alleles according to the stochastic error
model, for which  denotes the probability that, at each
marker locus, the allele is changed.We consider the cases
for (no genotyping errors), , p 0  p 0.001  p
, and . Sometimes, a genotyping error be-0.005  p 0.01
comes visible by leading to MI. We consider three dif-
ferent error options (EOs) as strategies for responding
to such an inconsistency: (EO1) genotypes of a marker
locus with MI are considered to be unknown in all in-
dividuals of the family; (EO2) in the presence of MI for
at least one marker locus, the whole family is discarded
from the analysis; and (EO3) a marker locus showing
MI is typed again, and it is assumed that the retyping
results in error-free genotypes for this marker locus. The
number of family trios in a sample is denoted by N, and
we let , 200, or 1,000. Note that for EO2, theN p 100
number of families used for statistical analysis is gen-
erally smaller than N. For each combination of , EO,
and N, 1,000 samples are generated.
To analyze a simulated sample by the HS-TDT pro-
posed by Zhang et al. (2003), we discard the phase in-
formation. The ﬁrst step for statistical analysis is to
obtain haplotype estimates. This is achieved by the pro-
gram FAMHAP (Becker and Knapp, in press), which
applies a locus-iterative mode of the expectation-maxi-
mization (EM) algorithm (Dempster et al. 1977) to ob-
tain maximum-likelihood estimates of haplotype fre-
quencies in general nuclear families. Zhang et al. (2003)
discussed two different analysis options (AOs) to make
use of estimated haplotype frequencies in case of am-
biguous phase information in the families of the sample:
(AO1) each possible haplotype explanation of an am-
biguous family is weighted by its relative likelihood and
(AO2) each ambiguous family is assigned its most likely
haplotype explanation. Our simulated samples are an-
alyzed by both of these AOs. The HS-TDT requires a
permutation procedure to obtain the P value of the test.
For each sample, we estimate the P value by 10,000
permutations. The true type I error rate at nominal error
rate a is estimated by the fraction of the 1,000 replicated
samples resulting in a P value a.
The results are shown in tables 1 and 2. If there are
no genotyping errors (i.e., ), table 1 reveals a good p 0
agreement between nominal and true type I error rate,
irrespective of the AO used to handle ambiguous fam-
ilies. (Note that if there are no genotyping errors, no
MIs can occur, and, therefore, the EO is irrelevant.) Ta-
ble 2 gives estimated type I error rates for the three EOs
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and AO1. Results are virtually identical when the most
likely haplotype explanation is assigned to ambiguous
families (see table B in the online-only supplemental ma-
terial). As is obvious from table 2, the agreement be-
tween nominal and true type I error rate is disastrous
in the presence of genotyping errors. Even quite small
probabilities of genotyping errors lead to a dramatic
inﬂation of the type I error. For ﬁxed values of , the
extent of this inﬂation increases with increasing sample
size (N), as can be seen by comparing the second and
third row in table 2. For a large sample size of N p
family trios, an error probability of is1,000  p 0.1%
sufﬁcient to falsely reject the null hypothesis at a p
in almost every sixth study. For small values of N0.05
and large values of , the inﬂation of type I error is
slightly less pronounced for EO2 than for EO1, which
is explained by noting that EO2 leads to a decrease of
the sample size used for the analysis. At ﬁrst sight, it
may be surprising that no essential decrease of the in-
ﬂation of type I error is obtained by employing EO3.
However, correcting genotypes leading to MIs does not
affect errors in the nontransmitted haplotypes.
What are possible limitations of our simulation study?
We assume a speciﬁc haplotype structure in the popu-
lation, such that only 29 different haplotypes are present.
Indeed, we conjecture that with larger haplotype diver-
sity, the effect of genotyping errors on the type I error
rate of the HS-TDT will be less pronounced than in the
example considered here. On the other hand, however,
it does not seem very realistic to expect that the HS-
TDTwill have substantial power to detect a disease locus
in a region in which the markers are in complete or
nearly complete linkage equilibrium in the population.
Thus, although our example describes a speciﬁc situa-
tion, it does not seem to be unrealistic for the genetic
structure of a region for which the HS-TDT may have
a good chance of detecting a disease locus. A second
possible limitation is that we employed a quite simple
error model that assumes the independence of genotyp-
ing errors from factors such as marker locus, true allele,
etc. However, we see no reason why the behavior of the
type I error rate of the HS-TDT should be qualitatively
different for more complex models of genotyping errors.
Additionally, we are convinced that the range 0.1%–1%
for the probability () of a genotyping error considered
here is not too pessimistic for currently available meth-
ods of high-throughput genotyping.
In summary, we have shown that the correctness of
genotypes is crucial for obtaining meaningful results by
the HS-TDT. We have also demonstrated that the re-
typing of only those marker loci that show MIs within
a family is useless. A more extreme approach is to ge-
notype all marker loci in all families in duplicate, which
is very expensive and certainly not very popular with
geneticists responsible for generating genotypes. How-
ever, unless extreme care is taken to guarantee the in-
tegrity of the data analyzed by the HS-TDT, this inter-
esting and appealing method has the potential of
becoming a mighty tool for the enlargement of the heap
of false-positive association results in human genetics.
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Reply to Knapp and Becker
To the Editor:
Knapp and Becker (2004 [in this issue]) have argued
that genotyping errors may lead to an inﬂated type I
